Peter Clark to beta Catenin
This is a "connection" page, showing publications Peter Clark has written about beta Catenin.
Connection Strength
1.777
-
Polosukhina D, Love HD, Moses HL, Lee E, Zent R, Clark PE. Pharmacologic Inhibition of ß-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor. Oncol Res. 2017 Nov 02; 25(9):1653-1664.
Score: 0.578
-
Yi Y, Polosukhina D, Love HD, Hembd A, Pickup M, Moses HL, Lovvorn HN, Zent R, Clark PE. A Murine Model of K-RAS and ß-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor. J Urol. 2015 Dec; 194(6):1762-70.
Score: 0.496
-
Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman EJ, de Caestecker M, Moses HL, Zent R. ß-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors. Am J Pathol. 2011 Dec; 179(6):3045-55.
Score: 0.388
-
Nlandu-Khodo S, Neelisetty S, Phillips M, Manolopoulou M, Bhave G, May L, Clark PE, Yang H, Fogo AB, Harris RC, Taketo MM, Lee E, Gewin LS. Blocking TGF-ß and ß-Catenin Epithelial Crosstalk Exacerbates CKD. J Am Soc Nephrol. 2017 Dec; 28(12):3490-3503.
Score: 0.144
-
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol. 2017 04; 11(4):405-421.
Score: 0.141
-
Lin-Tsai O, Taylor JA, Clark PE, Adam RM, Wu XR, DeGraff DJ. Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):512-6.
Score: 0.030